Galectin-9 Emerges as New Target for Chronic Lymphocytic Leukemia Immunotherapy
Multi-omics study reveals exhausted T-cells in CLL lymph nodes and identifies galectin-9 as a promising therapeutic target for overcoming immune evasion.
Summary
Researchers used advanced multi-omics techniques to map T-cell dysfunction in chronic lymphocytic leukemia (CLL) patients. They analyzed blood, bone marrow, and lymph node samples, discovering that lymph nodes contain the most severely exhausted T-cells. The study identified galectin-9, a protein that binds to the TIM3 receptor, as a key driver of immune suppression. When researchers blocked galectin-9 in mouse models, disease progression slowed and T-cell function improved. Higher galectin-9 levels correlated with worse survival in CLL and other cancers, suggesting it helps tumors evade immune detection.
Detailed Summary
Chronic lymphocytic leukemia (CLL) patients show remarkably poor responses to immunotherapy, with anti-PD1 antibodies achieving very low response rates. This comprehensive study sought to understand why T-cells fail to control CLL by mapping immune dysfunction across different body compartments.
Researchers analyzed T-cells from 22 CLL patients using single-cell RNA sequencing, mass cytometry, and tissue imaging. They examined blood, bone marrow, and lymph node samples, comparing them to healthy controls. The team also used a CLL mouse model to test potential therapeutic targets.
Lymph nodes emerged as the most immunosuppressive environment, containing severely exhausted CD8+ T-cells and abundant regulatory T-cells. These exhausted T-cells showed high expression of inhibitory receptors like PD1 and TIM3. Importantly, the researchers identified T-cell populations predicted to recognize CLL tumor antigens, suggesting the immune system initially attempts to fight the cancer before becoming overwhelmed.
The study pinpointed galectin-9 as a critical immune suppressor. This protein binds to TIM3 receptors on T-cells, promoting exhaustion and dysfunction. When researchers blocked galectin-9 in mice, they observed reduced disease progression and fewer TIM3+ exhausted T-cells. Analysis of patient data revealed that higher galectin-9 expression correlated with worse survival in CLL, kidney cancer, and brain tumors.
These findings suggest galectin-9 inhibition could restore T-cell function and improve immunotherapy responses in CLL. The research provides a roadmap for developing combination therapies that target both tumor cells and the immunosuppressive microenvironment, potentially transforming treatment outcomes for CLL patients.
Key Findings
- Lymph nodes contain the most severely exhausted T-cells compared to blood or bone marrow
- Galectin-9 protein drives T-cell exhaustion through TIM3 receptor binding
- Blocking galectin-9 in mice reduced disease progression and improved T-cell function
- Higher galectin-9 levels predict worse survival in CLL and other cancers
- CLL-reactive T-cells are present but become dysfunctional in lymph nodes
Methodology
The study used single-cell RNA sequencing, mass cytometry with 42 antibodies, and multiplex tissue imaging to analyze 5.29 million T-cells from 22 CLL patients and 13 healthy controls. Researchers validated findings in a CLL mouse model with galectin-9 inhibition experiments.
Study Limitations
The study focused primarily on CLL patients and used a single mouse model for validation. Clinical trials are needed to confirm galectin-9 inhibition safety and efficacy in humans. The optimal timing and combination strategies for galectin-9 targeting remain to be determined.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.